Evidence map›Paper›PMID 30604274›Full record

ArticlePathology oncology research : POR2020

Immunohistochemical Profile of Tumor Suppressor Proteins RASSF1A and LATS1/2 in Relation to p73 and YAP Expression, of Human Inflammatory Bowel Disease and Normal Intestine.

Pinelopi Nterma, Eleni Panopoulou, Eleni Papadaki-Petrou, Martha Assimakopoulou

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Hippo pathway in intestinal diseases: focusing on ferroptosis.Frontiers in cell and developmental biology · 2023
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Pinelopi NtermaDepartment of Anatomy, Histology and Embryology, School of Medicine, University of Patras, Biomedical Sciences Research Building, 1 Asklipiou, Gr-26504, Rion, Greece.
Eleni PanopoulouDepartment of Pathology, General Hospital Agios Andreas, Patras, Greece.
Eleni Papadaki-PetrouDepartment of Anatomy, Histology and Embryology, School of Medicine, University of Patras, Biomedical Sciences Research Building, 1 Asklipiou, Gr-26504, Rion, Greece.
Martha AssimakopoulouDepartment of Anatomy, Histology and Embryology, School of Medicine, University of Patras, Biomedical Sciences Research Building, 1 Asklipiou, Gr-26504, Rion, Greece. massim@upatras.gr.ORCID http://orcid.org/0000-0002-8990-4000
University of Patras · GRAgios Andreas Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The intestinal neoplastic transformation is a possible risk of chronic inflammatory bowel disease (IBD). Previous evidence in mice IBD provides a role for the RAS-association domain family tumor suppressor protein 1 A (RASSF1A), in the repairing process following mucosa epithelium damage, through cooperation with the HIPPO-signaling molecules p73, and YAP. HIPPO pathway which has been implicated in stem cell activity includes as key components for signal transduction the large tumor suppressor homology Ser/Thr kinases LATS1/2. The aim of this study was to assess immunohistochemically, using specific antibodies, the RASSF1A and LATS1/2 expression patterns in a cohort of patients with IBD including 52 ulcerative colitis (UC), 24 Crohn's disease (CD) and 24 IBD unclassified (IBD-U), compared with normal intestine from non-IBD patients (control group). The relationship between subtypes of IBD and RASSF1A and LATS1/2 expression, both individually and related to p73 and YAP/pYAP(Ser127) proteins was also investigated. Quantitative analyses of the immunohistochemical findings in mucosa cells revealed a significantly decreased expression in UC and IBD-U for RASSF1A expression and a significantly elevated expression in UC, IBD-U, and CD for LATS1/2 expression compared with normal mucosa (P < 0.05). However, ROC curve analysis showed that only LATS1/2 could differentiate IBD from control group. RASSF1A expression was significantly correlated with LATS1/2 in UC with dysplasia (P < 0.0001), and p73 in UC (P < 0.001), and IBD-U (P < 0.02). The expression of all proteins did not differ significantly between subtypes of IBD (P ≥ 0.05). RASSF1A-LATS1/2 co-expression was mainly observed in IBD samples. These findings suggest that tumor suppression proteins RASSF1A and LATS1/2 may be involved in the pathogenesis of human IBD and imply a potential cooperation of RASSF1A, and HIPPO signaling pathways in human bowel inflammation.

Indexed as

Adaptor Proteins, Signal TransducingAdultAgedAged, 80 and overBiomarkersFemaleHumansImmunohistochemistryInflammatory Bowel DiseasesIntestine, LargeMaleMiddle AgedProtein Serine-Threonine KinasesTranscription FactorsTumor Protein p73Tumor Suppressor ProteinsAdaptor Proteins, Signal TransducingBiomarkersLATS1 protein, humanLATS2 protein, humanProtein Serine-Threonine KinasesRASSF1 protein, humanTP73 protein, humanTranscription FactorsTumor Protein p73Tumor Suppressor ProteinsYAP1 protein, humanYAP-Signaling ProteinsCrohn’s diseaseHIPPO pathwayHuman inflammatory bowel diseaseLATS1/2RASSF1AUlcerative colitis

Identifiers

PMID30604274
OpenAlexW2908453801

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.